Luteolin Circadian Rhythm Support: Celery Compound Phases Your Clock

The Oasis Health Journal · Submitted July 27, 2026 · 5:31 PM EDT

By Tito Barragan · Edited by Nadine Cho

Your circadian clock is not romantic. It is a feedback loop of proteins that takes about twenty-four hours to complete, and when it drifts out of sync with the actual day, your body starts arguing with the sun.

Light resets it. Meals nudge it. And according to a 2021 screen of Japanese traditional medicines published in Scientific Reports, certain plant compounds can alter it in ways researchers are still mapping. One of those is luteolin, a yellow bioflavonoid you have probably eaten in celery, parsley, and the green things your tía insists cure everything. The luteolin circadian rhythm connection emerged from a screen of a hundred and thirty-seven crude drug extracts tested on cells carrying clock gene reporters.

The question is whether luteolin circadian rhythm research done in cells and fish larvae means anything when you are a full-size human trying to fall asleep before midnight.

What Happened in the Circadian Screen (And What Made the Cut)

Researchers at a Japanese university took a hundred and thirty-seven crude drug extracts, most of them from Kampo formulas, and tested them on human U2OS cells carrying a luciferase reporter fused to the Bmal1 gene. Translation: the cells glow in rhythm with their internal clock, and when a compound changes that rhythm, the lab gets a graph.

Twelve percent of the library did something to the clock. The rest did nothing, or the cells died, or the effect was too weak to call. Luteolin-containing extracts showed up in the active group.

They confirmed the hits in rat fibroblasts expressing a Per2 reporter, then in explanted lung tissue from Per2::Luciferase knockin mice, then in live zebrafish larvae. The clock kept shifting. The fish did not complain.

Then the team looked at what the active compounds had in common. More than half of them, including luteolin, are known to target AKT signaling or its upstream regulators. AKT is a serine-threonine kinase that sits at the intersection of growth signaling and metabolic control, and it regulates circadian phase in multiple model systems.

When they knocked down all three AKT isoforms with siRNA, the circadian period changed. When they treated cells with an AKT activator or inhibitor, same thing. Luteolin fits the pattern. It is not a lone agent; it is part of a mechanistic club.

Why a Bioflavonoid From Celery Shows Up in a Clock Study

Luteolin is not new. It appears in celery, parsley, thyme, green peppers, chamomile, and about fifty other plants your ancestors considered food or medicine depending on the century. Structurally it is a flavone, which means it has two benzene rings connected by a three-carbon bridge with a ketone on it, and if you just felt your eyes glaze over, that is fine. The shape is what lets it dock onto enzymes and receptors that do not expect a vegetable.

Pharmacologically, luteolin has been described as an anti-inflammatory, an antioxidant, a phosphodiesterase inhibitor, and a modulator of about six different signaling cascades depending on the cell type and the journal you are reading. It gets into cells. It changes gene expression. Whether it does so at doses you can achieve by eating parsley is the part nobody has settled.

The circadian angle is newer. The Scientific Reports team was not looking for bioflavonoid circadian support specifically; they were screening everything in the Kampo cabinet to see what landed. Luteolin landed because it altered clock gene oscillation in four experimental systems, and because its known targets overlap with pathways that entrain the clock.

Entrainment is the process by which your internal rhythm locks onto an external cue, usually light. The retina detects dawn, signals the suprachiasmatic nucleus in the hypothalamus, and a cascade of kinases and transcription factors resets the loop. AKT is part of that cascade. Luteolin, at least in a dish, appears to modulate it.

What the Study Showed and What It Extremely Did Not

The 2021 screen demonstrated that luteolin-containing crude drug extracts altered circadian period and amplitude in reporter cells, in tissue explants, and in zebrafish. It identified AKT signaling as a shared mechanism among active compounds. It reproduced the effect with purified luteolin in several of the follow-up assays.

What it did not do: give luteolin to a person and measure sleep latency, total sleep time, wake after sleep onset, or circadian phase markers like dim-light melatonin onset. Did not test whether oral luteolin reaches the brain in a relevant concentration. Did not compare it to melatonin, to bright light therapy, or to going to bed at the same time every night like your body has been asking you to do for years.

Cell-based circadian assays are the opening round. They tell you a molecule can hit the target. They do not tell you it will, in a living organism, at a dose that does not also require you to eat your body weight in celery.

A second limit: the study used crude extracts, not isolated luteolin, for most of the screen. Crude drugs contain dozens of compounds. Assigning credit to one flavonoid is reasonable when you follow up with the purified molecule, which they did. But it also means the effect might require co-factors, might depend on the extraction solvent, might not survive your stomach acid. We do not know yet.

The Circadian Machinery and Where Luteolin Circadian Rhythm Effects Might (or Might Not) Fit

Your clock is built from a transcription-translation feedback loop. CLOCK and BMAL1 proteins form a heterodimer, enter the nucleus, and activate Period and Cryptochrome genes. PER and CRY proteins accumulate, get phosphorylated by casein kinases, re-enter the nucleus, and inhibit CLOCK-BMAL1. The loop takes about twenty-four hours. Light resets it by degrading CRY. Food, temperature, and certain signaling molecules can shift the phase.

AKT phosphorylates BMAL1 and modulates its activity. Luteolin, according to prior literature cited in the Scientific Reports paper, can inhibit AKT in some contexts and activate it in others, depending on dose and cell type. The circadian effect observed in the screen is consistent with modulation of that axis, but the directionality and dose-response curve in human neurons remain unknown.

A 2024 review in Neurology International listed luteolin's close relative kaempferol as a candidate for repurposing in circadian-related headache disorders, based on similar AKT-targeting logic. Both flavonoids appear in the same dietary sources. Neither has been through a phase-two trial for sleep or circadian outcomes.

The 2025 review in Molecules on melatonergic receptor agonists does not mention luteolin, because luteolin does not bind melatonin receptors. Its mechanism, if it has one in humans, is parallel, not redundant.

Should You Expect a Luteolin Sleep Supplement to Fix Your Bedtime

No manches, we are not there yet.

If you want natural circadian support, the interventions with the most evidence are the ones that sound like a poster in a pediatrician's office: consistent sleep and wake times, morning light exposure, dim evening light, no large meals right before bed, no stimulants after two in the afternoon. These work because they directly entrain the clock through pathways we understand.

Luteolin has preliminary mechanistic data in non-human models. It does not yet have a dosing study, a bioavailability curve, or a sleep trial. Eating celery and parsley will not hurt you and might help in ways unrelated to your circadian clock, but it is not a replacement for the boring interventions that actually move the needle.

The Scientific Reports screen is useful because it narrows the search space. It tells future researchers which molecules are worth testing in humans, which pathways to measure, and which traditional formulas might contain active agents. It does not tell the consumer to start taking luteolin before bed and expect results.

Where the Research Goes Next (And What We Are Still Waiting For)

The logical follow-up is a pharmacokinetic study: give oral luteolin to volunteers, measure plasma and cerebrospinal fluid levels, see if it crosses the blood-brain barrier in a dose that could plausibly engage AKT signaling in hypothalamic neurons. If it does, then you design a small trial with actigraphy, sleep logs, and salivary melatonin sampling to see if it shifts circadian phase.

You compare it to placebo and to a known phase-shifter like bright light or exogenous melatonin. You measure not just whether people report sleeping better, but whether their molecular clock, assayed from buccal cells or hair follicles, actually moves.

That study has not been published. It might be in progress. It might never happen, because funding for circadian trials on a non-patentable plant compound is hard to get and the return on investment is unclear.

In the meantime, luteolin remains a molecule of interest, a lead from a traditional medicine screen, and a compound your body has been processing since the first time you ate a salad. Whether it is a circadian tool or just a bystander in a complex extract is still the question the lab has to answer.

Orale, the data says it can shift the clock in a zebrafish. Your mileage, as a mammal with a mortgage, may vary.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs, Molecules (Basel, Switzerland) (2025).
2. Cluster Headache and Hypoxia: Breathing New Life into an Old Theory, with Novel Implications, Neurology international (2024).
3. AUTOPHAGY IN THE EYE: FROM PHYSIOLOGY TO PATHOPHYSIOLOGY, Autophagy reports (2023).
4. Modulation of circadian clock by crude drug extracts used in Japanese Kampo medicine, Scientific reports (2021).